{"id":51576,"date":"2020-05-05T00:00:00","date_gmt":"2020-05-05T05:00:00","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=51576"},"modified":"2022-11-29T15:45:33","modified_gmt":"2022-11-29T20:45:33","slug":"joe-reilly-with-david-bell-usa-mobile-drug-testing-video-blog","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/joe-reilly-with-david-bell-usa-mobile-drug-testing-video-blog\/","title":{"rendered":"Joe Reilly with David Bell, USA Mobile Drug Testing \u2013 Video Blog"},"content":{"rendered":"\n

It was great to see David Bell and other USAMDT franchisees from around the country at the March 8th<\/sup> USA Mobile Drug Testing annual conference.  This conference was held in conjunction with the National Drug & Alcohol Screening Association (NDASA) conference in Jacksonville, Florida March 9 \u2013 11, 2020.<\/p>\n\n\n\n

David Bell is the CEO of USA Mobile Drug Testing (USAMDT). <\/a> Incorporated in 2008, USA Mobile Drug Testing (USAMDT\u00ae) is a privately held corporation headquartered in beautiful Tampa Bay, Florida. As a franchise system, USAMDT compliance specialists operate all around the United States.  The primary focus is mobile onsite drug testing.<\/p>\n\n\n\n

Celebrating 10 years since the first franchisee launched a USAMDT business, the Franchise Owners are Compliance Specialists creating value added relationships with clients locally and nationwide.  The USAMDT mobile compliance specialists go to schools to test students, sporting events to test amateur and professional athletes, as well as to a broad variety of businesses to test employees while on the job.<\/p>\n\n\n\n

In this video, Joe Reilly<\/a> catches up with USAMDT CEO David Bell.  Reilly has a long history with USAMDT serving as the Senior Compliance Officer. Joe Reilly provides guidance on regulatory matters and best practices on drug testing business operations.  Joe has been involved in training of each of the USAMDT franchise owners and many of the USAMDT employees. Joe continues to oversee all USAMDT training programs and drug free workplace policy development for customers across the USA.<\/p>\n\n\n\n

David Bell came on board with USAMDT early on starting as Vice President and moving on to CEO.  Joe Strom<\/a> is the founder of USAMDT and remains active providing guidance and consultation and serves as a member of the USAMDT Board of Directors.   Joe Strom had a vision of an opportunity to create the business model of on-site mobile collections with a complete compliance package offered to employers. Strom is passionate about providing services with strict compliance and best practices.  His goal was for his compliance specialists to be trusted advisors to employers helping them navigate drug testing and drug free workplace programs.<\/p>\n\n\n\n

David Bell is active in the drug testing industry and writes many articles which can be viewed on the USAMDT blog.<\/a>  He is also extremely active as a member of the National Drug & Alcohol Screening Association (NDASA)<\/a>.<\/p>\n\n\n\n

National Drug Screening (NDS)<\/a> is proud to host this video blog.  NDS regularly utilizes the services of USAMDT for mobile on-site collections and after hours request for over 2000 NDS clients around the United States.  Drug testing TPA\u2019s looking for mobile collection services should contact USAMDT<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

It was great to see David Bell and other USAMDT franchisees from around the country at the March 8th USA Mobile Drug Testing annual conference.  This conference was held in conjunction with the National Drug & Alcohol Screening Association (NDASA) conference in Jacksonville, Florida March 9 \u2013 11, 2020. David Bell is the CEO of […]<\/p>\n","protected":false},"author":12,"featured_media":54208,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"50873,50940,51539,50866,51002,50869","_relevanssi_noindex_reason":"","footnotes":""},"categories":[77],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51576"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=51576"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/51576\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/54208"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=51576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=51576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=51576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}